ERBB2 and breast cancer: Estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer accounts for approximately 65–75% of all breast cancer cases [2, 3], and the expected 5-year survival rate for patients with ER+/HER2- metastatic breast cancer is 34% [4].